April 24, 2020 Ken Reali Re: Amendment to Employment Agreement Dear Ken:Employment Agreement • November 10th, 2020 • Bioventus Inc. • Surgical & medical instruments & apparatus
This letter will serve to amend your employment agreement with Bioventus LLC dated as of March 14, 2020 (the “Agreement”) as follows:
June 12, 2020 Anthony P. Bihl, III Dear Tony:Bioventus Inc. • November 10th, 2020 • Surgical & medical instruments & apparatus
This will letter will set forth the understanding between you and Bioventus LLC (the “Company”) in connection with your exercise of the put rights and the Company’s repurchase of the 333,330 Profit Interest Units granted to you under the Management Incentive Plan (the “MIP”) as set forth in that certain Management Incentive Plan Award Agreement dated as of December 2, 2013 (the “MIP Agreement’) and the payment due to you under the Bioventus Phantom Profits Interest Plan (the “Phantom Plan”) for the Phantom Profits Interest Units granted to you under that certain Phantom Profit Interest Plan Award Agreement dated April 21, 2016 (the “PPI Agreement”), as a result of your retirement from the Company.
AMENDED AND RESTATED LICENSE AGREEMENT – US BETWEEN BIOVENTUS LLC AND Q-MED AB AND NESTLÉ SKIN HEALTH S.A. December 9, 2016License Agreement • November 10th, 2020 • Bioventus Inc. • Surgical & medical instruments & apparatus • New York
This Amended and Restated License Agreement – US (together with all schedules and exhibits attached hereto, the “Agreement”), is made and entered into this December 9, 2016 (the “Amendment Effective Date”), by and among Q-Med AB, a limited liability company organized under the laws of the Kingdom of Sweden with corporate registration number 556258-6882 (“Q-Med”), Nestlé Skin Health S.A., a corporation organized under the laws of Switzerland (“NSH”), and Bioventus LLC, a limited liability company organized under the laws of Delaware (“Bioventus”). Each of (i) Q-Med and NSH, on the one hand, and (ii) Bioventus, on the other hand, shall be referred to herein as a “Party” and collectively as the “Parties.” This Agreement shall amend, supersede and replace the Current US License Agreement (as defined below).
AMENDED AND RESTATED SUPPLY AGREEMENT - US BETWEEN BIOVENTUS LLC AND Q-MED AB December 9, 2016Supply Agreement • November 10th, 2020 • Bioventus Inc. • Surgical & medical instruments & apparatus • New York
This Amended and Restated Supply Agreement – US (together with all schedules and exhibits attached hereto, this “Agreement”) is entered into as of December 9, 2016 (the “Amendment Effective Date”), between Bioventus LLC, a limited liability company organized under the laws of Delaware (“Bioventus”), Q-Med AB, a limited liability company organized under the laws of the Kingdom of Sweden with corporate registration number 556258-6882 (“Q-Med”) and Nestlé Skin Health S.A., a corporation organized under the laws of Switzerland, as guarantor of Q-Med’s obligations hereunder (“Guarantor”). Each of (i) Q-Med and Guarantor, on the one hand, and (ii) Bioventus, on the other hand, shall be referred to herein as a “Party” and collectively as the “Parties.” This Agreement shall amend, supersede and replace the Current US Supply License Agreement (as defined below).
ContractLicense, Supply and Distribution Agreement • November 10th, 2020 • Bioventus Inc. • Surgical & medical instruments & apparatus
[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.
